[Jessica]

In this video, Amgen staff from around the world share their thoughts on the corporate values that set the company apart and make working at Amgen more than just a job.



Amgen deal for Onyx possible within week: sources
(Reuters) - Onyx Pharmaceuticals Inc is close to selling itself to larger rival Amgen Inc as the cancer drugmaker's high stock price has discouraged other companies from making a counteroffer so far, according to people familiar with the matter.

Companies are negotiating a price of $130 per share, or nearly $9.5 billion based on shares outstanding.

Source: http://in.reuters.com/article/2013/08/07...VX20130807

Amgen Sales Top Analysts' Estimate on Growth of Key Drugs

(bloomberg) Sales of top drugs Enbrel, for rheumatoid arthritis, and Neulasta, for patients taking chemotherapy, increased 9 percent and 10 percent in the quarter, respectively, Amgen said. Amgen also is developing new products and trying to expand its business outside the U.S. as it seeks new revenue.

Amgen raised its 2013 forecast, saying it expects total revenue for the year to be at the upper end of $17.8 billion to $18.2 billion, and for earnings excluding certain items to be $7.30 a share to $7.45 a share.


Amgen signs autoimmune pact with Japan's Teijin
Amgen has linked up with Teijin Pharma to develop treatments for autoimmune diseases. The agreement centres around small molecule drugs discovered by the Japanese drugmaker that target ROR?


http://careers.amgen.com/en/